Financing round-up: Numares Health, Arincare, MinervaX, Jalon Therapeutics, Herantis Pharma

Finland: Herantis Pharma, a developer of disease-modifying therapies for Parkinson’s disease, has been invited to negotiate a €2.5m (US$2.7m) grant agreement with EIC, with the option to receive additional funding through an equity investment. The grant will fund the further development of Herantis’ lead product HER-096 for Parkinson’s disease. Herantis’ application successfully passed the EIC…

You must be a HMI Subscriber to view this content.

Subscribe Now »